Back to top

pharmaceuticals: Archive

Nalak Das

Buy 3 High Dividend-Paying Stocks With Attractive Short-Term Returns

Three large-cap stocks ??? AES, PFE and UNM ??? currently offer attractive short-term returns along with a high dividend rate.

PFENegative Net Change UNMPositive Net Change AESNo Net Change

Zacks Equity Research

Incyte Announces Promising New Data on Oncology Candidate at ESMO

INCY's INCB123667 data show the candidate's potential as a differentiated treatment option for cancers with increased cyclin E1 activity, amplification and/or overexpression in cells predictive of CDK2 dependency.

INCYNegative Net Change SNDXNegative Net Change KRYSNegative Net Change FULCNegative Net Change

Zacks Equity Research

Regeneron, SNY Win FDA Approval for a Broader Dupixent Label

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change

Zacks Equity Research

Instil Bio Stock Skyrockets 641% in One Week: Here's Why

A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.

MRKNegative Net Change SMMTPositive Net Change TILPositive Net Change BVSPositive Net Change

Zacks Equity Research

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study

Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage study.

ILMNNegative Net Change KRYSNegative Net Change FULCNegative Net Change IMRXPositive Net Change

Zacks Equity Research

MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.

SNYNegative Net Change GSKNegative Net Change MRKNegative Net Change MRNANegative Net Change

Kinjel Shah

TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?

Teva's reasonable valuation, an improving pipeline and the prospect of growth in sales and profits are good enough reasons for those who own the stock to stay invested.

SNYNegative Net Change JNJNegative Net Change TEVANegative Net Change ABBVNegative Net Change

Zacks Equity Research

Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq

The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.

NVSNegative Net Change RHHBYNegative Net Change LLYPositive Net Change

Zacks Equity Research

Gilead Stock Rises as HIV Prevention Injection Meets Study Goals

GILD reports the success of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, in a second late-stage study for the prevention of HIV.

GSKNegative Net Change GILDPositive Net Change KRYSNegative Net Change FULCNegative Net Change

Kinjel Shah

Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More

FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly injection, Wegovy.

REGNNegative Net Change SNYNegative Net Change JNJNegative Net Change NVONegative Net Change

Zacks Equity Research

Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study

AURA stock up as lead candidate shows tumor control and visual acuity preservation abilities in eye cancer patients over 12 months of treatment.

ILMNNegative Net Change KRYSNegative Net Change FULCNegative Net Change AURANegative Net Change

Kinjel Shah

NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise

Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.

NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change

Zacks Equity Research

Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More

Terns Pharmaceuticals and Summit Therapeutics are in the spotlight following positive updates on key candidates.

GSKNegative Net Change SMMTPositive Net Change IMVTNegative Net Change RLAYNegative Net Change TERNNegative Net Change

Zacks Equity Research

Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.

NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change

Zacks Equity Research

FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis

With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.

JNJNegative Net Change LLYPositive Net Change ABBVNegative Net Change

Ahan Chakraborty

Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks

Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.

NVSNegative Net Change RHHBYNegative Net Change PFENegative Net Change LLYPositive Net Change

Zacks Equity Research

Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug

RHHBY's data on experimental obesity drug, CT-996, disappoints investors on higher incidence of adverse events.

RHHBYNegative Net Change NVONegative Net Change LLYPositive Net Change

Zacks Equity Research

Eli Lilly and Hertz Global have been highlighted as Zacks Bull and Bear of the Day

Eli Lilly and Hertz Global have been highlighted as Zacks Bull and Bear of the Day.

AMZNPositive Net Change HTZNegative Net Change LLYPositive Net Change GOOGLPositive Net Change SHOPPositive Net Change

Ethan Feller

Bull of the Day: Eli Lilly (LLY)

Eli Lilly stock boasts both defensive and growth characteristics

LLYPositive Net Change

Zacks Equity Research

Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?

BMY's recent rally gives investors a ray of hope after the downturn earlier on in 2024. However, we advise investors not to be over-optimistic at this point and look before they leap.

BMYPositive Net Change PFENegative Net Change MRKNegative Net Change

Zacks Equity Research

Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals

This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.

REGNNegative Net Change SNYNegative Net Change NVSNegative Net Change RHHBYNegative Net Change

Zacks Equity Research

Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering

IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.

AZNNegative Net Change GSKNegative Net Change BIIBNegative Net Change IONSPositive Net Change

Zacks Equity Research

Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug

CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.

BMYPositive Net Change MRKNegative Net Change CRVSPositive Net Change FULCNegative Net Change

Mark Vickery

Top Stock Reports for Visa, AbbVie & Anheuser-Busch

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and Anheuser-Busch InBev SA/NV (BUD), as well as two micro-cap stocks Servotronics, Inc. (SVT) and United-Guardian, Inc. (UG).

VNegative Net Change MCOPositive Net Change LLYPositive Net Change BUDNegative Net Change KMIPositive Net Change ABBVNegative Net Change SVTPositive Net Change UGPositive Net Change

Zacks Equity Research

Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda

Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.

MRKNegative Net Change SMMTPositive Net Change FULCNegative Net Change BVSPositive Net Change